Physician profile
Jordan Cunningham
NPI 1457899577
$2,598.96
in general payments reported to CMS, 2019-2025
31 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,209 · 2022: $657 · 2023: $128 · 2024: $171 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $690.90 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $260.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $238.97 | 2021-2023 | |
| Sk Life Science, INC. | $232.02 | 2024-2025 | Xcopri |
| Lilly USA, LLC | $111.57 | 2021-2025 | Zepbound |
| Amgen INC. | $102.01 | 2021-2022 | |
| Abbvie INC. | $100.37 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $86.29 | 2021-2022 | |
| Pfizer INC. | $74.60 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $71.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $70.45 | 2021-2022 | |
| Mylan Specialty L.P. | $52.64 | 2022 | |
| Biogen, INC. | $51.28 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $50.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.76 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $40.19 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $32.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $28.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.08 | 2021 | |
| Esperion Therapeutics, INC. | $26.93 | 2021 | |
| Dexcom, INC. | $24.26 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $22.13 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.81 | 2021 | |
| Glaxosmithkline, LLC. | $20.74 | 2022 | |
| Boston Scientific Corporation | $19.55 | 2024 | Watchman Flx |
| Supernus Pharmaceuticals, INC. | $19.39 | 2021 | |
| Amag Pharmaceuticals, INC. | $18.28 | 2022 | |
| Currax Pharmaceuticals LLC | $16.26 | 2023 | Contrave |
| Lundbeck LLC | $15.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.65 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.12 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.